Intarcia Therapeutics, a Boston, MA-based biotech company, raised $200m in financing.
The round was led by RA Capital with participation from Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, and other three additional large top-tier institutional investors.
The company will use the funds to further develop ITCA 650 – its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM.
Led by Kurt Graves, Chairman, President and Chief Executive Officer, Intarcia is developing and commercializing innovative therapies that merge medicine with technology to treat chronic serious diseases.
The company’s therapies aim to enhance treatment outcomes by optimizing and improving the efficacy, eliminating the need for life-long injections, ensuring compliance and persistency over time with up to once-yearly dosing, and by improving the tolerability of drug therapies.
Beyond ITCA 650, it has additional early development programs ongoing for weight regulation to control obesity.
Intarcia had raised $210m in equity and debt financing in November of 2012.